Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine
As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines remain to be evaluated in terms of immunogenicity against live clinical isolates. We report boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X), EG.5.1(10.5X), and JN.1(4.7X) variants.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
medRxiv : the preprint server for health sciences - (2024) vom: 26. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Nguyenla, Xammy Huu [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 08.04.2024 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1101/2024.03.25.24304857 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370753100 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370753100 | ||
003 | DE-627 | ||
005 | 20240408233553.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240408s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2024.03.25.24304857 |2 doi | |
028 | 5 | 2 | |a pubmed24n1369.xml |
035 | |a (DE-627)NLM370753100 | ||
035 | |a (NLM)38585892 | ||
035 | |a (PII)2024.03.25.24304857 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Nguyenla, Xammy Huu |e verfasserin |4 aut | |
245 | 1 | 0 | |a Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 08.04.2024 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a As novel SARS-CoV-2 variants continue to emerge, the updated XBB.1.5 monovalent vaccines remain to be evaluated in terms of immunogenicity against live clinical isolates. We report boosting of IgG(2.1X), IgA(1.5X), and total IgG/A/M(1.7X) antibodies targeting the spike receptor-binding domain and neutralizing titers against WA1(2.2X), XBB.1.5(7.4X), EG.5.1(10.5X), and JN.1(4.7X) variants | ||
650 | 4 | |a Preprint | |
700 | 1 | |a Bates, Timothy A |e verfasserin |4 aut | |
700 | 1 | |a Trank-Greene, Mila |e verfasserin |4 aut | |
700 | 1 | |a Wahedi, Mastura |e verfasserin |4 aut | |
700 | 1 | |a Tafesse, Fikadu G |e verfasserin |4 aut | |
700 | 1 | |a Curlin, Marcel |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2024) vom: 26. März |w (DE-627)NLM310900166 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:26 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.03.25.24304857 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 26 |c 03 |